Home > Healthcare > Pharmaceuticals > Finished Drug Form > Transthyretin Amyloidosis Treatment Market

Transthyretin Amyloidosis Treatment Market Share

  • Report ID: GMI8484
  • Published Date: Mar 2024
  • Report Format: PDF

Transthyretin Amyloidosis Treatment Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their product portfolios. The companies are actively adopting multi-pronged approaches to address the rising demand for new treatments and strengthen their market presence.

Transthyretin Amyloidosis Treatment Market Companies

Prominent players operating in the transthyretin amyloidosis treatment industry are as mentioned below:

  • Acrotech Biopharma, LLC
  • Alnylam Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Astellas Pharma Inc.
  • BridgeBio Pharma, Inc.
  • Bristol-Myers Squibb Company
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Prothena Biosciences Limited
  • Pfizer Inc.
  • SOM Innovation Biotech, S.L.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Transthyretin amyloidosis treatment industry was valued at USD 5.9 billion in 2023 and is poised to expand at 7.5% CAGR between 2024 and 2032 owing to the increasing prevalence of transthyretin amyloidosis, a rare genetic disorder, coupled with advancements in treatment options for rare diseases.

The ATTR-CM segment generated USD 4.7 billion in revenue in 2023 and is estimated to grow at a notable CAGR from 2024-2032 owing to the rising advancements in diagnostics techniques that aid in timely intervention.

North America accounted 37.6% revenue share of the transthyretin amyloidosis treatment industry in 2023 and is set to expand at a considerable growth rate through 2032 due to well-established healthcare infrastructure, and high awareness about rare diseases among healthcare professionals and patients.

Some of the top transthyretin amyloidosis treatment companies are Acrotech Biopharma, LLC, AstraZeneca PLC, Astellas Pharma Inc., BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, Ionis Pharmaceuticals, Inc., Johnson & Johnson, Prothena Biosciences Limited, Pfizer Inc., SOM Innovation Biotech, S.L.

Transthyretin Amyloidosis Treatment Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 299
  • Countries covered: 19
  • Pages: 170
 Download Free Sample